ClinicalTrials.gg
Active, not recruitingNCT07008001CATHAY ExtUpdated Nov 17, 2026

Assessment of DOT Spectacles in Chinese Children Extension

An interventional study of Novel spectacle lens design in Juvenile Myopia and Myopia, sponsored by SightGlass Vision, Inc.. Active, not recruiting at 5 sites in China. Open to participants aged 8 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by SightGlass Vision, Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
8 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Myopia by SightGlass Vision, Inc. — 3 open to participants now, 12 under way, none of them phase 3. Myopia · SightGlass Vision, Inc..

Planned enrollment
5th of 14
175 · median 71
Started
2025
with 1 other
No phase
14 of 14
3 open now
Primary completion
2026-12
later than 6 of 11 live
Registered
12th of 14
by date

Among the 14 studies in Myopia by SightGlass Vision, Inc., this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 14 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 12th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

3 of the 14 studies in Myopia by SightGlass Vision, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 8 Years to 16 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Myopia by SightGlass Vision, Inc., or all of them as a file.
02

Study summary

This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.

03

Conditions studied

  • Juvenile Myopia
  • Myopia

Browse trials for

04

Who can participate

Ages eligible
8 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previously a successfully completed participant in the CATHAY study (NCT05562622)
  2. Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day)
  3. Willingness to participate in the trial for 12 months without contact lens wear or any other myopia management intervention
  4. The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of and receive a fully executed copy of the form

Exclusion criteria

Exclusion Criteria:

1. Known allergy to proparacaine, tetracaine, or tropicamide or cyclopentolate

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
175 participants (estimated)

Study arms

  • Experimental
    SightGlass Vision Test Arm Groups I (formerly test group)

    Single vision, impact-resistant spectacle lenses

    Device: Novel spectacle lens design

  • Experimental
    SightGlass Vision Test Arm Groups II (formerly control group)

    Single vision, impact-resistant spectacle lenses

    Device: Novel spectacle lens design

Interventions

  • DeviceNovel spectacle lens design

    Use of spectacle lenses may reduce the rate of progression of juvenile myopia

06

What researchers measure

Primary outcomes

  1. Axial length Group I

    Change in axial length from baseline to 36 months

    Time frame: 12 months

  2. Axial length Group II

    Change in axial length from baseline to 12 months

    Time frame: 12 months

07

Study locations

5 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 16 months is above that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Sep 2026 → Dec 2026 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
Jun 6, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 31, 2026was Sep 2026
CompletionEst.
Jun 30, 2027was Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 17, 2026
Primary completion
Sep 30, 2026→Dec 31, 2026
Nov 17, 2026
Study completion
Dec 31, 2026→Jun 30, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 30, 2026→Dec 31, 2026
    Study completion Dec 31, 2026→Jun 30, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07008001
Lead sponsor
SightGlass Vision, Inc.
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Aug 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion